# Intra-Cellular Therapies, Inc. – Consensus ‘buy’ rating and -4.2% Downside Potential

- Link: https://www.directorstalkinterviews.com/intra-cellular-therapies-inc-consensus-buy-rating-and-4-2-downside-potential/4121183976
- Published: 2025-01-17T12:53:01+00:00
- Author: Charlotte Edwards

**Intra-Cellular Therapies, Inc.** with ticker code (ITCI) now have 11 market analysts
covering the stock. The analyst consensus now points to a rating of ‘buy’. The target
price High/Low ranges between $140.00 and $87.00 suggesting an average Analsyt target
price of $121.36. Now with the previous closing price of $126.71 this would indicate
that there is a downside of -4.2%. There is a 50 day moving average of $88.95 while
the 200 day moving average is $76.94. The company has a market cap of 13.41B. The
current share price for the company is: $126.26 USD

 The potential market cap would be $12,848,365,840 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $6.10 and
a -7.45% return on assets.

Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused
on the discovery, clinical development and commercialization of small molecule drugs
that address underserved medical needs primarily in neuropsychiatric and neurological
disorders by targeting intracellular signaling mechanisms within the central nervous
system (CNS). The Company’s product CAPLYTA is a treatment for depressive episodes
associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy
and as adjunctive therapy with lithium or valproate. The efficacy of CAPLYTA 42 
mg in bipolar depression was demonstrated in two positive Phase III placebo-controlled
bipolar depression studies, which evaluated the effects of CAPLYTA on depression
in adult patients with bipolar I or bipolar II disorder both as monotherapy (Study
404) and as adjunctive therapy with lithium or valproate (Study 402).

Share on: